目的 探討重組人腦鈉肽對急性心衰患者心腎功能及腦利鈉肽（BNP）的影響。方法 選取2011年1月-2016年12月鄭州市第七人民醫(yī)院收治的急性心力衰竭患者120例。隨機(jī)分為兩組，對照組在常規(guī)治療的基礎(chǔ)上給予硝普鈉，觀察組在常規(guī)治療的基礎(chǔ)上給予重組人腦鈉肽。用藥48 h后，觀察兩組患者的心功能改善情況、左心室射血分?jǐn)?shù)、血漿BNP水平、排尿量、血肌酐、血鉀濃度變化情況。結(jié)果 用藥后48 h，觀察組心功能改善的總有效率為83.34%，顯著優(yōu)于對照組的56.67%，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。與用藥前相比，兩組患者用藥后LVEF均明顯的升高，組內(nèi)差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組明顯高于對照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；用藥后兩組的血漿BNP水平均明顯降低，組內(nèi)差異有統(tǒng)計(jì)學(xué)意義（P<0.05），且觀察組明顯低于對照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；用藥后兩組的尿量均明顯增加，組內(nèi)差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組的多于對照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。與用藥前相比，兩組患者的血肌酐濃度均輕度升高，觀察組血鉀濃度輕微升高，對照組血鉀濃度輕微下降，差異均無統(tǒng)計(jì)學(xué)意義；停藥后，未見進(jìn)一步加劇。結(jié)論 應(yīng)用重組人腦鈉肽治療急性心力衰竭患者，可以改善患者的心功能情況，降低血漿BNP水平，利尿，對腎功能未見不良影響。

Objective To investigate the influence of BNP and heart and kidney function of recombinant human brain natriuretic peptide on acute heart failure treatment. Methods 120 cases from Jan. 2011 to Dec. 2016 in our hospital were chosen and randomly divided into two groups, the control group were given traditional treatment, the observation group were given brain natriuretic peptide on the basic of traditional treatment. The heart function, left ventricular ejection fraction, plasma BNP, urine output, serum creatinine, blood potassium concentration of two groups were compared. Results After 48 h, the total effective rate of the improvement of cardiac function in the observation group was 83.34%, which was significantly better than that of the control group 56.67%, the difference was statistically significant (P < 0.05). After treatment, the heart function, left ventricular ejection fraction, plasma BNP, urine output of two groups after treatment were better than before treatment (P < 0.05). And the heart function, LVEF ascending range, BNP concentration reduction and urine increased amount of observation group were better than control group (P < 0.05). The serum creatinine concentration of two groups were slighter higher than before, the blood potassium concentration of observation group after treatment was slighter higher than before, the blood potassium concentration of control group was slighter lower than before, which had no significant difference, and after discontinuation which had no further intensified. Conclusion The recombinant human brain natriuretic peptide could be treating for acute heart failure treatment, and improve the heart function, decreased the plasma BNP level, dieresis and which had no adverse reaction on kidney function.